A172 Orthotopic Mouse Model Service for Brain Cancer

The A172 orthotopic mouse model for brain cancer provides a well-characterized human glioblastoma xenograft platform that recapitulates the epithelial-like morphology, hypertriploid genomic complexity, and mesenchymal stemness traits of high-grade glioma within an immunodeficient host. Alfa Cytology delivers this specialized orthotopic model service with end-to-end technical support—from cell line authentication and stereotactic intracranial implantation into nude or NSG mice to longitudinal bioluminescence and MRI monitoring, histopathological endpoint analysis, and stemness marker profiling—empowering researchers to advance their glioblastoma drug discovery programs with precision.

Overview of A172 Orthotopic Mouse Model for Brain Cancer

The A172 cell line was established from a glioblastoma multiforme resected from a 53-year-old male patient and is catalogued as ATCC CRL-1620. Exhibiting epithelial-like morphology and adherent growth kinetics with a doubling time of approximately 44 hours, A172 represents a classic human glioblastoma model with a hypertriploid karyotype (modal chromosome number n = 80) harboring over 20 marker chromosomes per cell. The line displays a distinct mesenchymal signature, expressing CD90, CD105, fibroblast activation protein (FAP), and tenascin—markers associated with glioma stemness and tumor microenvironment remodeling. Notably, A172 cells demonstrate robust activation of Heat Shock Factor 1 (HSF1), which sustains SOX2-driven cancer stem cell properties and upregulates matrix metalloproteinase-2 (MMP-2), conferring invasive potential and intrinsic resistance to standard alkylating agents. Under sphere-forming conditions, HSF1 levels escalate further, enhancing the self-renewal capacity and tumorigenicity of the cells.

Fig 1. circPRKCI shRNA inhibits orthotopic A172 glioma growth in mice. (Zhang, Xuebang, et al., 2019)

As a human xenograft model, A172 requires implantation into immunodeficient hosts such as athymic nude mice or NSG mice to prevent rejection. When delivered orthotopically via stereotactic intracranial injection, A172 cells form well-circumscribed intracranial tumors that can be tracked longitudinally through luciferase-expressing derivatives (A172_Luc) using bioluminescence imaging. The model exhibits metabolic reprogramming characteristic of human glioblastoma, including elevated glycolytic flux, glutamine addiction, and lipid metabolic shifts, making it particularly suited for evaluating temozolomide sensitization strategies, HSF1 pathway inhibitors, and metabolic disruptors. Unlike syngeneic models, the A172 orthotopic xenograft allows direct testing of human-specific therapeutic modalities—including antibody-drug conjugates and humanized biologics—within a physiologically relevant brain microenvironment.

Cell Line Information: A172

The table below summarizes the essential characteristics of the A172 human glioblastoma cell line to guide model selection and experimental design for preclinical brain cancer studies.

Our Services

Alfa Cytology provides a comprehensive A172 orthotopic mouse model service tailored to your glioblastoma preclinical research objectives, encompassing STR-authenticated cell expansion, precision stereotactic intracranial implantation into nude or NSG hosts, longitudinal bioluminescence and MRI tumor tracking, and detailed histopathological, stemness-marker, and metabolic endpoint characterization. Our experienced neuro-oncology team ensures reproducible tumor engraftment, rigorous quality control, and flexible study architectures that integrate seamlessly with your therapeutic development workflow.

Workflow of A172 Orthotopic Mouse Model Construction

Construction of the A172 orthotopic glioblastoma model employs a refined stereotactic neurosurgical protocol optimized for immunodeficient hosts, ensuring high engraftment fidelity, minimal perioperative morbidity, and consistent intracranial tumor progression suitable for multi-week therapeutic evaluation. The workflow integrates cell quality verification, precision intracranial delivery, and longitudinal multimodal monitoring to generate robust, publication-quality preclinical datasets.

1. Cell Line Authentication and Expansion: A172 cells are authenticated by human STR profiling and expanded in high-glucose DMEM complete medium to ensure phenotypic stability, epithelial-like morphology integrity, and viability >95% prior to surgical preparation.
2. Luciferase Labeling (Optional): For longitudinal non-invasive monitoring, A172 cells are transduced with a luciferase-neomycin construct and selected under neomycin to generate A172_Luc pools with stable bioluminescent signal output.
3. Host Selection and Acclimatization: Immunodeficient mice—typically female athymic BALB/c nude mice or NSG mice aged 6–10 weeks—are acclimatized for at least one week with health screening and baseline body weight recording to minimize inter-animal variability.
4. Anesthesia and Surgical Preparation: Mice are anesthetized with isoflurane (induction 2.5%, maintenance 1–2%) or 2% pentobarbital sodium (80 mg/kg) delivered via intraperitoneal injection; the head is shaved, disinfected with alternating betadine and alcohol swabs, and secured in a stereotactic frame with a thermoregulated heating pad.
5. Stereotactic Coordinate Calibration: Bregma and lambda are identified after gentle periosteal reflection; a 0.9 mm burr hole is drilled at coordinates 2 mm lateral and 2 mm posterior to bregma, targeting the right striatum, with the dura mater left intact to minimize cortical trauma.
6. Intracranial Cell Injection: A Hamilton syringe or microinjector loaded with 5 µL of A172 cell suspension (1 × 10⁵ to 5 × 10⁵ viable cells in sterile PBS, with or without Matrigel) is inserted to a depth of 3.5–4 mm, and cells are slowly injected at 0.5 µL/30 s; the needle is held in place for 3–5 minutes to prevent reflux.
7. Cranial Closure and Postoperative Care: The burr hole is sealed with bone wax or sterile collagen sponge, the scalp incision is closed with surgical adhesive or sutures, and mice are recovered on a heated pad with analgesic support per institutional animal care guidelines.
8. Tumor Establishment Verification: Tumor engraftment is confirmed 5–10 days post-implantation via bioluminescence imaging (for A172_Luc lines) or contrast-enhanced micro-MRI; mice displaying confirmed tumor signals are randomized into vehicle and treatment cohorts.
9. Longitudinal Monitoring and In-Life Assessment: Tumor burden is tracked weekly via bioluminescence imaging, T2-weighted MRI, or micro-CT; concurrent recording of body weight, neurological deficit scoring, and overall clinical condition enables early detection of treatment-related toxicities.
10. Treatment Administration: Investigational agents—including temozolomide analogs, HSF1 inhibitors, metabolic disruptors, targeted small molecules, antibody-drug conjugates, or combination regimens—are administered according to protocol-defined schedules via intravenous, intraperitoneal, oral, or intracranial routes as appropriate.
11. Necropsy and Tissue Procurement: At study endpoint, brains are harvested en bloc, photographed, and sectioned coronally; tumor dimensions are measured, and tissue aliquots are allocated for formalin-fixed paraffin embedding, snap-freezing, and downstream molecular analysis.
12. Histopathological and Molecular Characterization: Tumor sections undergo H&E staining, IHC for Ki-67, CD90, CD105, SOX2, HSF1, MMP-2, and phospho-AKT, alongside metabolic profiling and flow cytometry to characterize stemness modulation, pathway engagement, and therapeutic response.
13. Data Integration and Reporting: All imaging, survival, biometric, and molecular data are compiled into a comprehensive study report with tumor growth curves, Kaplan-Meier survival analyses, neurological scoring summaries, and pharmacodynamic interpretations suitable for regulatory or publication use.

Fig 2. A172 Orthotopic Mouse Model construction workflow.

Case Study-A172 Orthotopic Mouse Model Development

In a representative preclinical program, the A172 orthotopic glioblastoma model was established in immunodeficient mice with reproducible intracranial tumor take and progressive bioluminescence signal expansion over a multi-week treatment window. Treatment cohorts receiving a novel HSF1 pathway inhibitor demonstrated dose-dependent reduction in tumor bioluminescence relative to vehicle controls, accompanied by decreased SOX2-positive stem cell fractions and diminished MMP-2 immunoreactivity in post-treatment tumor sections. A parallel combination arm pairing the HSF1 inhibitor with temozolomide showed enhanced therapeutic synergy, with improved tumor growth inhibition and extended survival compared to either monotherapy. Detailed quantitative datasets—including longitudinal bioluminescence tumor growth curves, body weight profiles, neurological scoring trends, and stemness-marker modulation data—are available for review; please reach out to our scientific team to discuss how these findings can inform your specific glioblastoma therapeutic strategy.

Why Choose Alfa Cytology?

Partnering with Alfa Cytology for your A172 orthotopic model program provides access to a human xenograft-focused service platform with deep expertise in glioblastoma stemness biology, immunodeficient host management, and metabolic pathway analysis.

• Established proficiency with human glioblastoma xenograft systems and optimized stereotactic protocols that yield consistent A172 intracranial engraftment in nude and NSG hosts.
• Integrated luciferase-labeling and longitudinal bioluminescence imaging infrastructure for real-time, non-invasive tumor monitoring and early pharmacodynamic readouts.
• Specialized stemness and mesenchymal marker profiling capabilities spanning HSF1, SOX2, CD90, CD105, and MMP-2 to dissect glioma stem cell modulation and invasive potential.
• Metabolic phenotyping expertise—including glycolytic flux, glutamine dependency, and lipid metabolism analysis—to evaluate metabolic disruptors and sensitization strategies.
• Flexible study designs supporting monotherapy, combination, sequential, and biomarker-stratified arms tailored to human-specific therapeutic modalities including antibody-drug conjugates.
• Rigorous cell authentication, health surveillance, and GLP-aligned documentation practices that uphold data integrity for IND-enabling and peer-review standards.

Contact Us

To explore how the A172 orthotopic mouse model can advance your glioblastoma preclinical program, we invite you to reach out to us for a confidential scientific consultation. Our neuro-oncology specialists will evaluate your therapeutic target, propose a customized study design leveraging the unique mesenchymal stemness and metabolic features of this human glioblastoma xenograft, and outline a clear roadmap to generating the high-quality data your discovery team requires. Contact us today and let Alfa Cytology drive your next preclinical milestone in brain cancer research.

For research use only. Not intended for any clinical use.